Request Demo
Last update 08 May 2025
Advanced Accelerator Applications (Italy) Srl
Last update 08 May 2025
Overview
Tags
Urogenital Diseases
Neoplasms
Digestive System Disorders
Peptide Conjugate Radionuclide
Therapeutic radiopharmaceuticals
Diagnostic radiopharmaceuticals
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
CTR20243344
一项在前列腺特异性膜抗原（PSMA）阳性寡转移性前列腺癌（OMPC）成年男性患者中比较镥(177Lu)vipivotide tetraxetan（AAA617）与观察组延迟去势或疾病复发的国际、前瞻性、开放性、多中心、随机化III期研究
[Translation] An international, prospective, open-label, multicenter, randomized phase III study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus observation for delayed castration or disease recurrence in adult men with prostate-specific membrane antigen (PSMA)-positive oligometastatic prostate cancer (OMPC)
CTR20240678
一项在PSMA PET扫描阳性去势抵抗性前列腺癌患者中评价镥 [177Lu] vipivotide tetraxetan（AAA617）单药和镥 [177Lu] vipivotide tetraxetan（AAA617）联合雄激素受体抑制剂的国际多中心、前瞻性、开放标签、随机、非比较性II期研究（PSMACare）。
[Translation] An international, multicenter, prospective, open-label, randomized, noncomparative phase II study evaluating lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and in combination with an androgen receptor inhibitor in patients with PSMA PET scan-positive castration-resistant prostate cancer (PSMACare).
CTR20230581
一项在未曾接受过紫杉烷类药物的进展性转移性去势抵抗性前列腺癌中国男性患者中评价 [177Lu]Lu-PSMA-617 vs. 更换另一种雄激素受体定向疗法的开放标签、多中心、随机、II 期研究
[Translation] An open-label, multicenter, randomized, phase II study evaluating [177Lu]Lu-PSMA-617 versus a switch to another androgen receptor-directed therapy in Chinese men with progressive metastatic castration-resistant prostate cancer who have not received prior taxane therapy
100 Clinical Results associated with Advanced Accelerator Applications (Italy) Srl
Login to view more data
Login to view more data
100 Deals associated with Advanced Accelerator Applications (Italy) Srl
Login to view more data
100 Translational Medicine associated with Advanced Accelerator Applications (Italy) Srl
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 29 May 2025
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 3 Clinical
1
1
NDA/BLA
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free